Home >> Research Area >>Neuroscience>>AChR>> Biperiden

Biperiden

Anticholinergic drug CAS# 514-65-8

Biperiden

Catalog No. BCC4274----Order now to get a substantial discount!

Product Name & Size Price Stock
Biperiden: 5mg $23 In Stock
Biperiden: 10mg Please Inquire In Stock
Biperiden: 20mg Please Inquire Please Inquire
Biperiden: 50mg Please Inquire Please Inquire
Biperiden: 100mg Please Inquire Please Inquire
Biperiden: 200mg Please Inquire Please Inquire
Biperiden: 500mg Please Inquire Please Inquire
Biperiden: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Biperiden

Number of papers citing our products

Chemical structure

Biperiden

3D structure

Chemical Properties of Biperiden

Cas No. 514-65-8 SDF Download SDF
PubChem ID 2381 Appearance Powder
Formula C21H29NO M.Wt 311.46
Type of Compound N/A Storage Desiccate at -20°C
Synonyms KL 373
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
SMILES C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
Standard InChIKey YSXKPIUOCJLQIE-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Biperiden

DescriptionBiperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate. It also has a prominent central blocking effect on M1 receptors [2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty, whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness

References:
[1]. Pehl C, et al. Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. Aliment Pharmacol Ther. 1998 Oct;12(10) [2]. Kornhuber J, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8) [3]. Myhrer T, et al. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. Pharmacol Biochem Behav. 2008 Jun;89(4):633-8.

Biperiden Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Biperiden Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Biperiden

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.2107 mL 16.0534 mL 32.1069 mL 64.2137 mL 80.2671 mL
5 mM 0.6421 mL 3.2107 mL 6.4214 mL 12.8427 mL 16.0534 mL
10 mM 0.3211 mL 1.6053 mL 3.2107 mL 6.4214 mL 8.0267 mL
50 mM 0.0642 mL 0.3211 mL 0.6421 mL 1.2843 mL 1.6053 mL
100 mM 0.0321 mL 0.1605 mL 0.3211 mL 0.6421 mL 0.8027 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Biperiden

Biperiden is an anticholinergic drug [1].

As an anticholinergic drug, biperiden is first used in the treatment of Parkinson's disease. It is a competitive antagonist of muscarinic receptor. It has been believed that in the patients of PD, a reduction of intranigral dopamine concentrations results in a relative imbalance between the dopaminergic and cholinergic neurological pathways. The anticholinergics can correct the imbalance through reducing the degree of neurotransmission mediated by neostriatal acetylcholine. Biperiden is also used to treat extrapyramidal side effects of antipsychotic drugs. In addition, the misuse of biperiden causing delirium has been reported in several clinical settings [1, 2].

References:
[1] Brocks D R. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci, 1999, 2(2): 39-46.
[2] Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden Dependence: Case Report and Literature Review. Case reports in psychiatry, 2012, 2012.

Featured Products
New Products
 

References on Biperiden

Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy.[Pubmed:28328695]

Pediatr Emerg Care. 2018 Nov;34(11):e217-e218.

Methylphenidate is a stimulant drug commonly prescribed to individuals with attention-deficit/hyperactivity disorder. The suggested underlying mechanism of acute dyskinesias is dopaminergic transmission increase. We describe a 9-year-old boy with a diagnosis of attention-deficit/hyperactivity disorder admitted to emergency clinic with primarily orofacial and extremity dyskinesia after administration of a first dose of 18 mg OROS (osmotic [controlled] release oral) methylphenidate (Concerta). OROS methylphenidate was discontinued, and the patient's symptoms resolved within 20 minutes after injection of Biperiden by intravenous route (0.04 mg/kg). We wish to emphasize that acute orofacial dyskinesia and extremity dyskinesia can be observed during methylphenidate therapy and that Biperiden can be successfully used in the treatment of this unpleasant condition. To the best of our knowledge, this is the first report of the use of Biperiden therapy in this condition. This case report highlights the importance for physicians of awareness of dyskinesia as a potential adverse effect of methylphenidate therapy and indicates benefit of Biperiden therapy.

The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of mice.[Pubmed:28216067]

Pharmacol Biochem Behav. 2017 Jun;157:47-57.

Preclinical and clinical studies suggest that neuronal muscarinic acetylcholine receptor (M-AchR) antagonists have antidepressant-like properties. Despite the recent interest in bicaudal C homolog 1 gene (BICC1) as a target for the treatment of depression, the upstream signaling molecules that regulate BICC1 are unknown, and very few studies have addressed the involvement of BICC1 in the antidepressant-like effects of the selective M1-AchR inhibitor, Biperiden. Growing evidence indicates that activation of brain-derived neurotrophic factor (BDNF)/tropomyosin-related kinase receptor B (TrkB) signaling may be involved in antidepressant-like activities. In this study, we investigated the role of BDNF/TrkB signaling in the regulation of BICC1 expression in the chronic unpredictable stress (CUS) mouse model of depression. Furthermore, we also examined whether BDNF/TrkB signaling contributes to the antidepressant-like effects of Biperiden via down-regulation of BICC1 in the hippocampus and prefrontal cortex of mice. Our current data show that CUS exposure induced significant depression-like behaviors, down-regulation of BDNF/TrkB signaling and up-regulation of BICC1 in the hippocampus and prefrontal cortex of mice. However, Biperiden significantly alleviated the CUS-induced abnormalities. Moreover, we found that the effects of Biperiden were antagonized by pretreatment with the TrkB antagonist K252a. Our results indicate that BDNF/TrkB signaling may be the major upstream mediator of BICC1 involvement in the antidepressant-like effects of Biperiden.

Effects of biperiden and acute tryptophan depletion and their combination on verbal word memory and EEG.[Pubmed:28210777]

Psychopharmacology (Berl). 2017 Apr;234(7):1135-1143.

BACKGROUND: Research on the neurobiological foundations of memory has shown that multiple neurotransmitters play an important role in memory processing. To study the interaction between neurotransmitters such as acetylcholine and serotonin, pharmacological models can be used. In this study, we tested the effects of the muscarinic M1 antagonist Biperiden, acute tryptophan depletion (ATD), and the interaction between the two on episodic memory using the verbal learning task. METHODS: The study was conducted according to a double-blind, placebo-controlled, four-way crossover design. Seventeen participants received Biperiden (2.0 mg), ATD (SolugelP), a combination of both, or a placebo in counterbalanced order with a wash out of at least 7 days. A verbal learning task was performed while recording electroencephalography. The task consisted of an immediate and delayed recall as well as a recognition part. RESULTS: Results revealed decreased scores on the delayed recall after Biperiden and ATD separately but no significant interaction between the two. However, the event-related potential components P3b, N400, and P600 did show an interaction during encoding. CONCLUSION: These results indicate that both BIP and ATD impair episodic memory. However, an interaction between the serotonergic and cholinergic system on memory performance is not supported.

Description

Biperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker.

Keywords:

Biperiden,514-65-8,KL 373,Natural Products,AChR, buy Biperiden , Biperiden supplier , purchase Biperiden , Biperiden cost , Biperiden manufacturer , order Biperiden , high purity Biperiden

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: